American Association for Cancer Research
10780432ccr152342-sup-156015_1_supp_3227242_nxqz30.ppt (236.5 kB)

Supplemental Figure 5 - Pooled standard curves. from The Prognostic and Predictive Value of Soluble Type IV Collagen in Colorectal Cancer: A Retrospective Multicenter Study

Download (236.5 kB)
posted on 2023-03-31, 18:46 authored by Hans Christian Rolff, Ib Jarle Christensen, Ben Vainer, Lars Bo Svendsen, Rikke Løvendahl Eefsen, Michael Wilhelmsen, Ida Katrine Lund, Gunilla Høyer-Hansen, Hans Jørgen Nielsen, Martin Illemann

Shows the pooled standard curves for the two batches. Figure legend in the end the "Supplementary data. Appendix 3. Adjusting for batch variation" file.


Department of Surgical Gastroenterology and Transplantation, Rigshospitalet

Danish Cancer Society

The Kornerup Fund

The Aage and Johanne Louis-Hansen Fund

The Aase and Ejnar Danielsen Fund

The Walter and O. Kristiane Christensen Fund

The Kathrine and Vigo Skovgaard Fund

Den Midtjyske Bladfond

The Agnes and Poul Friis Fund

The Glunz and Jensen Fund

The Sophus and Astrid Jacobsen Fund

The Arvid Nilsson Fund

The Danish Bank Fund

The Johannes Fog Fund

The Eva and Henry Fraenkel Fund

The Hartmann Bros. Fund

The KID Fund

The Henrik Henriksen Fund

The King Christian X's Fund

The Oda and Hans Svenningsen Fund

The Else and Mogens Wedell-Wedellsborg Fund

The Einar Willumsen Fund

The Willy and Ingeborg Reinhard Fund

The Friedrich and Else Boehm Fund

The Toyota Fund Denmark

The IMK Fund

The Danish Medical Research Fund

The Beckett Fund

Hvidovre University Hospital



Purpose: To investigate the prognostic and predictive biomarker value of type IV collagen in colorectal cancer.Experimental Design: Retrospective evaluation of two independent cohorts of patients with colorectal cancer included prospectively in 2004–2005 (training set) and 2006–2008 (validation set). Plasma samples were available from 297 (training set) and 482 (validation set) patients. Type IV collagen determinations were performed using an ELISA. From the training set, 222 tumors were available for IHC. Clinical and follow-up data were retrieved from patient files and national registries.Results: High levels of type IV collagen showed independent prognostic significance in both cohorts with hazard ratios (HRs; for a one-unit change on the log base 2 scale) of 2.25 [95% confidence intervals (CIs), 1.78–2.84; P < 0.0001] and 2.24 (95% CI, 1.75–2.86; P < 0.0001) for the training and validation set, respectively. The prognostic impact was present both in patients with metastatic and nonmetastatic disease. The predictive value of the marker was investigated in stage II and III patients. In the training set, type IV collagen was prognostic both in the subsets of patients receiving and not receiving adjuvant antineoplastic therapy. However, in the validation set, the prognostic effect of the marker vanished when looking at patients who received adjuvant antineoplatic therapy (HR 0.90; 95% CI, 0.42–1.93) but was still present in the group not receiving adjuvant chemotherapy (HR 2.88; 95% CI, 1.98–4.21).Conclusions: The results indicate clinical validity of type IV collagen as a prognostic biomarker in colorectal cancer, although the suggested predictive role of the marker should be validated. Clin Cancer Res; 22(10); 2427–34. ©2015 AACR.